2026-04-17T04:30:42Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2281172026-04-08T14:00:41Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Amador Prous, Concha author Ambrosioni, Juan author Martín Carbonero, Luz author Hidalgo-Tenorio, Carmen author Tiraboschi, Juan Manuel author Moreno, Santiago author 2026-03-16T11:39:55Z 2026-03-16T11:39:55Z 2025-12-29 2026-02-25T10:31:40Z Integrase strand inhibitor (INSTI)-based antiretroviral regimens are the preferred choices for treating people with human immunodeficiency virus (PWH). The once-daily single-tablet combination of INSTI bictegravir, co-formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), has shown effectiveness and good tolerability in randomized clinical trials, both in treatment-na & iuml;ve (TN) and virologically suppressed patients switched to this regimen. Real-world evidence represents clinical practice and may fill data gaps left by piv otal studies. Based on literature search for real-world studies in Spain within five years, and using clinical trial data as a contextual framework, this narrative review synthesizes observational experience with BIC/FTC/TAF, focusing on the interplay between comorbidities, advanced age, and treatment outcomes from underrepre sented subgroups in clinical trials. This fixed-dose combination proved effective and well-tolerated for TN and treatment-experienced PWH, with low virological failure even in difficult-to-treat patients. Low rates of treatment discontinuations due to adverse events or drug-drug interactions aligned with clinical trial findings. Farmacoepidemiologia Antiretrovirals Pharmacoepidemiology Antiretroviral agents Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years